Two Sigma Investments, LP Editas Medicine, Inc. Transaction History

Two Sigma Investments, LP

$42.3 Billion
Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,358,589 shares of EDIT stock, worth $3.27 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,358,589

Previous 540,588 151.32%

Holding current value

$3.27 Million

Previous $2.52 Million 83.52%

% of portfolio

0.01%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $2.77 Million - $4.88 Million	818,001 Added 151.32%	1,358,589 $4.63 Million
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $3.96 Million - $6.17 Million	-847,394 Reduced 61.05%	540,588 $2.52 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $487,966 - $768,390	-69,412 Reduced 4.76%	1,387,982 $10.3 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $1.21 Million - $2.14 Million	192,806 Added 15.25%	1,457,394 $14.8 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $1.92 Million - $2.59 Million	278,168 Added 28.2%	1,264,588 $9.86 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $1.76 Million - $3.18 Million	277,511 Added 39.15%	986,420 $8.12 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $1.71 Million - $2.81 Million	-243,897 Reduced 25.6%	708,909 $5.14 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $451,351 - $716,629	-54,249 Reduced 5.39%	952,806 $8.45 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $3.82 Million - $6.09 Million	313,759 Added 45.26%	1,007,055 $12.3 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $2.49 Million - $5.31 Million	-248,796 Reduced 26.41%	693,296 $8.2 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $277,826 - $545,195	-19,732 Reduced 2.05%	942,092 $17.9 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $15.5 Million - $23.7 Million	583,709 Added 154.37%	961,824 $25.5 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $5.12 Million - $9.51 Million	130,394 Added 52.64%	378,115 $15.5 Million
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $17.7 Million - $32.1 Million	-566,169 Reduced 69.56%	247,721 $14 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $29.1 Million - $66.5 Million	733,936 Added 917.95%	813,890 $34.2 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $8.26 Million - $25.7 Million	-305,225 Reduced 79.24%	79,954 $5.61 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $2.39 Million - $3.17 Million	-85,291 Reduced 18.13%	385,179 $10.8 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1.69 Million - $3.13 Million	91,207 Added 24.05%	470,470 $13.9 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $1.99 Million - $4.39 Million	-133,969 Reduced 26.1%	379,263 $7.52 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $3.99 Million - $6.67 Million	204,564 Added 66.27%	513,232 $15.2 Million
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $2.95 Million - $3.52 Million	131,130 Added 73.86%	308,668 $7.02 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $3.1 Million - $4.2 Million	151,155 Added 572.93%	177,538 $4.39 Million
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $2.25 Million - $3.05 Million	-115,548 Reduced 81.41%	26,383 $645,000
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $2 Million - $3.5 Million	110,201 Added 347.31%	141,931 $3.23 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $2.33 Million - $3.23 Million	-84,124 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $2.64 Million - $3.45 Million	84,124 New	84,124 $3.01 Million

Others Institutions Holding EDIT

# of Institutions

247

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $166M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Editas Medicine, Inc. Transaction History